



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 23-D-013**

You asked:

Please note that we have provided this information for the period December 2022 to March 2023.

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab – 53
- Dupilumab – 32
- Omalizumab - 59
- Reslizumab - 0
- Mepolizumab – 23
- Tezepelumab - 0

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups:

- Age 6 – 11 - 0
- Age 12 – 17 - <5
- Age 18 and above - 166

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with:

- Dupilumab - 0
- Omalizumab - <5

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under



Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

